Fluorescence Image-Guided Lymphadenectomy in Robotic Gastrectomy

NCT ID: NCT03931044

Last Updated: 2019-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-30

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gastric cancer is a worldwide challenge due to its spread, even epidemic in some areas, and the high mortality rates. Lymphadenectomy is considered the fundamental step during radical gastrectomy. In recent years, some researchers have tried to find a way to improve the surgical identification of the lymphatic drainage routes and lymph node stations. This new surgical frontier is the so called "navigation surgery". Among the different reported solutions, lately, the indocyanine green (ICG) has drawn attention. It is a fluorescence dye, that can be detected in the near infrared spectral band (NIR). The development of specific fluorescence imaging devices has allowed surgeons to visualize tumors, vascular and lymphatic structures. The Da Vinci Xi robotic system has an integrated imaging technology that has been used in colo-rectal and hepato-biliary surgery. However, up to date, the combined use of fluorescence imaging and robotic technology has not been evaluated during lymphadenectomy in gastric cancer.

The general design of the present study is to evaluate the role of fluorescence imaging during robotic lymphadenectomy for gastric cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background Gastric cancer is the fourth most widespread cancer in the world and is characterized by high mortality rates \[1, 2\]. A multidisciplinary context, in which surgery plays the main role, is essential to offer the best therapeutic strategy. Lymph node involvement in gastric cancer is present in 2-18% when the depth of the tumor invasion is limited to the mucosal or submucosal layer, but rises to 50% when the tumor involves the subserosa \[3\]. Lymphadenectomy is a fundamental surgical phase that must guarantee the oncological radicality and allow an appropriate tumor staging. Although it is among the most relevant factors influencing long-term survival, its extension and standardization is still the subject of much debate. The two latest editions of the Japanese Gastric Cancer Association (JGCA) guidelines \[4\] recommend a dissection on different levels (D1, D1 +, D2) depending on the type of gastrectomy and the clinical stage of the tumor. In recent years, some researchers have tried to apply the concept of "sentinel lymph node" to gastric cancer \[5-7\]. Although some do not consider that terminology the appropriate one in the context of gastric cancer, because of the multidirectional gastric lymphatic flows, several studies have highlighted interesting aspects, such as: limiting an extensive lymphatic dissection when not necessary, identifying the drainage routes outside the standard anatomical planes, possible assistance in minimally invasive procedures \[8\]. Most of the experiences in lymph nodes mapping were performed with a radio-isotope (Tc99m) associated or not with the intraoperative use of vital dyes (Blue dye). More recently, the properties of the ICG have been studied. This is a fluorescence dye, that can be detected in the NIR \[9, 10\]. The development of imaging tools using "NIR / ICG" technology is therefore an innovative approach for visualizing tumors, vascular structures, lymphatic channels, and lymph nodes \[11\]. Some advantages of the ICG are: reduced toxicity, absence of radioactivity, low cost, safe administration both intravenously and endoscopically through the submucosa or subserosa, protein binding without changing molecular structures, macrophages interaction at the lymph node level. Devices for fluorescence imaging are currently available in both open and minimally invasive surgery.

In this field, robotic surgery has been becoming of great interest thanks to the manufacturing of new instruments which, compared to laparoscopy, allow to improve manual skills and gentleness in challenging movements \[12\]. The Da Vinci Xi robotic system has also produced an innovative imaging technology for ICG visualization made up with a laser source integrated in the robotic camera (Firefly). The surgeon at the console has therefore a 3-D vision that can switch to the fluorescence mode without the need to change the camera. Few clinical experiences have been reported to date \[12\]. Published articles refer to assistance in colo-rectal and hepato-biliary surgery for vessels or biliary structures visualization, while its use during lymph node dissection for gastric cancer has not yet been the subject of study protocols.

Hypothesis: fluorescence imaging during lymphadenectomy in gastric cancer can significantly improve the quality of the dissection through a better visualization of anatomical planes and allow tailored dissections. Moreover, the tumor status in the fluorescent nodes could predict the nodes status in the overall specimen with high accuracy rate.

Methods General study design: the overall objective is verifying the feasibility and the role of a lymphadenectomy assisted by fluorescence imaging during robotic gastrectomy.

Two levels of investigation are planned:

* to detect the possible advantages of a fluorescence-guided surgery ("Navigation Surgery");
* to evaluate the possibility of considering the lymph nodes labeled by the ICG as predictive of the state of tumor diffusion ("Targeted Surgery") Type of study: Interventional study.

Specific aims:

1. To verify the ability of the procedure to highlight the main tumor lymphatic drainage pathways.
2. To validate the concept of Navigation Surgery in gastric surgery by comparing the group of the experimental procedure with a control group undergoing the same type of surgery but not assisted by fluorescence.
3. To find a correlation between the nodes marked by the ICG and the remaining nodes removed during the procedure.
4. To identify the characteristics of those patients in whom the ICG can effectively discriminate the type of lymphadenectomy to be performed.

Data collection: the following information will be collected for each patient.

\- General variables: demographic, histopathological, intra and post-operative features, complications. - Specific variables: total number of lymph nodes retrieved (LNs), Fluorescent lymph nodes (FLNs), metastatic LNs, LNs by station, FLNs outside the standard dissection plane, FLNs status (positive or negative for tumor), non-fluorescent LNs status

Definitions and subdivision of patients:

* True positive patients: patients in which FLNs positive for tumor are detected when LNs positive for tumor are found in the analysis of the surgical specimen.
* False positive patients: patients in which FLNs positive for tumor are detected when LNs negative for tumor are found in the analysis of the surgical specimen.
* True negative patients: patients in which FLNs negative for tumor are detected when LNs negative for tumor are found in the analysis of the surgical specimen.
* False negative patients: patients in which FLNs negative for tumor are detected when LNs positive for tumor are found in the analysis of the surgical specimen.

Sample size: considering the volume of patients included in published studies available in the literature on the use of fluorescence imaging and adding that the present project is the first to describe the use of robotic technology with fluorescence assistance in gastric cancer, a total of 20 patients will be enrolled for the experimental procedure. An additional sample including 20 patients will be the control group, based on the same eligibility criteria. The total sample of patients planned for the present study is therefore of 40 subjects.

Statistical analysis: SPSS v23 will be used to perform data analysis. The dichotomous variables will be expressed as numbers and percentages, while the continuous variables as mean and standard deviation, or median and IQR (minimum and maximum values). For the comparison with the control group, the continuous variables will be analyzed with the T test for independent samples and a value of P \<0.05 will be considered statistically significant.

Impact on clinical practice and healthcare system: this project can pave the way for a new concept of lymphadenectomy in gastric cancer involving minimally invasive surgery. Patients could benefit from a more tailored approach to their disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Sentinel Lymph Node

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Image-Guided Robotic Gastrectomy

The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).

A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.

The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.

Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence.

Group Type EXPERIMENTAL

Image-Guided Robotic Gastrectomy

Intervention Type PROCEDURE

The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.

Robotic Gastrectomy

Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Image-Guided Robotic Gastrectomy

The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of gastric cancer proved through the endoscopic biopsy
* cT1 - cT3
* cN0

Exclusion Criteria

* history of allergies related to iodine
* pregnancy
* cT4,
* cN +
* distant metastases
* estimated sizes \> 4cm
* synchronous malignant tumors in other organs
* ASA score ≥ 4
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

International Study Group on Minimally Invasive Surgery for Gastric Cancer

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amilcare Parisi

Director of the Department of Digestive Surgery - St. Mary's Hospital of Terni

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale di Forlì "G.B. Morgagni" - AUSL della Romagna - U.O.C. di Chirurgia e Terapie Oncologiche Avanzate

Forlì, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera di Terni "Santa Maria" - S.C. di Chirurgia Digestiva

Terni, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacopo Desiderio, MD

Role: CONTACT

+393497531121

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Davide Cavaliere, MD

Role: primary

Jacopo Desiderio, MD

Role: primary

+393497531121

References

Explore related publications, articles, or registry entries linked to this study.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017 Jan;20(1):1-19. doi: 10.1007/s10120-016-0622-4. Epub 2016 Jun 24. No abstract available.

Reference Type BACKGROUND
PMID: 27342689 (View on PubMed)

Kitagawa Y, Fujii H, Mukai M, Kubota T, Otani Y, Kitajima M. Radio-guided sentinel node detection for gastric cancer. Br J Surg. 2002 May;89(5):604-8. doi: 10.1046/j.1365-2168.2002.02065.x.

Reference Type BACKGROUND
PMID: 11972551 (View on PubMed)

Yoshida M, Kubota K, Kuroda J, Ohta K, Nakamura T, Saito J, Kobayashi M, Sato T, Beck Y, Kitagawa Y, Kitajima M. Indocyanine green injection for detecting sentinel nodes using color fluorescence camera in the laparoscopy-assisted gastrectomy. J Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:29-33. doi: 10.1111/j.1440-1746.2012.07067.x.

Reference Type BACKGROUND
PMID: 22486868 (View on PubMed)

Bu L, Shen B, Cheng Z. Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev. 2014 Sep 30;76:21-38. doi: 10.1016/j.addr.2014.07.008. Epub 2014 Jul 24.

Reference Type BACKGROUND
PMID: 25064553 (View on PubMed)

Marano A, Priora F, Lenti LM, Ravazzoni F, Quarati R, Spinoglio G. Application of fluorescence in robotic general surgery: review of the literature and state of the art. World J Surg. 2013 Dec;37(12):2800-11. doi: 10.1007/s00268-013-2066-x.

Reference Type BACKGROUND
PMID: 23645129 (View on PubMed)

Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol. 2013 Oct 10;31(29):3704-10. doi: 10.1200/JCO.2013.50.3789. Epub 2013 Sep 9.

Reference Type BACKGROUND
PMID: 24019550 (View on PubMed)

Kitagawa Y, Fujii H, Kumai K, Kubota T, Otani Y, Saikawa Y, Yoshida M, Kubo A, Kitajima M. Recent advances in sentinel node navigation for gastric cancer: a paradigm shift of surgical management. J Surg Oncol. 2005 Jun 1;90(3):147-51; discussion 151-2. doi: 10.1002/jso.20220.

Reference Type BACKGROUND
PMID: 15895450 (View on PubMed)

Tani T, Sonoda H, Tani M. Sentinel lymph node navigation surgery for gastric cancer: Does it really benefit the patient? World J Gastroenterol. 2016 Mar 14;22(10):2894-9. doi: 10.3748/wjg.v22.i10.2894.

Reference Type BACKGROUND
PMID: 26973385 (View on PubMed)

Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013 Sep;10(9):507-18. doi: 10.1038/nrclinonc.2013.123. Epub 2013 Jul 23.

Reference Type BACKGROUND
PMID: 23881033 (View on PubMed)

Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5. Epub 2012 Jun 1.

Reference Type BACKGROUND
PMID: 22658655 (View on PubMed)

Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009 Aug 8;374(9688):477-90. doi: 10.1016/S0140-6736(09)60617-6. Epub 2009 Jul 20.

Reference Type BACKGROUND
PMID: 19625077 (View on PubMed)

Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995 Mar;82(3):346-51. doi: 10.1002/bjs.1800820321.

Reference Type BACKGROUND
PMID: 7796005 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IG-MIG Vers. 1.0-05.03.2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.